Enthea, the healthcare provider that specializes in psychedelic therapy, announced on Tuesday that it will “launch its services into 40 markets across the U.S. next year as well as grow Enthea’s customer base and provider network to further its mission of providing affordability and access to safe and effective psychedelic-assisted therapies for all who can benefit.”
The ambitious launch is the byproduct of a “successful $2M seed round raise, led by Tabula Rasa Ventures, the first psychedelic accelerator for early-stage startups,” the company said in the announcement.
Enthea says that the driving force behind the new endeavor is to improve access to potentially breakthrough psychedelic treatment amid an ever-spiraling mental health crisis in the United States.
The company asserts that it is “helping in this mental health crisis by bringing employer funding for these new treatments,” saying that “traditional health insurers are years away from adding this coverage, the cost
